{{Rsnum
|rsid=2835285
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Chromosome=21
|Orientation=plus
|Gene=CBR3
|position=36135469
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=CBR3,CBR3-AS1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 3.1 | 96.9
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2835285
|Name_s=CBR3:Val93Ile
|Gene_s=CBR3, RPS9P1
|Feature=
|Evidence=PubMed ID:20007405
|Annotation=Risk or phenotype-associated allele: T. Phenotype: In a study of bacterial expressed and purified human CBR3 proteins, the 93Ile variant had significantly reduced maximal reaction velocity (V(max)) for both anthracyclines compared with the wild-type enzyme. Type of association: FA.
|Drugs=daunorubicin; doxorubicin
|Drug Classes=ANTHRACYCLINES AND RELATED SUBSTANCES
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291864
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}